alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
### Stratigraphy and petroleum possibilities of lower Upper Devonian (Frasnian and lower Famennian) strata, Southwestern Utah

By: Edward J. Biller

                            https://doi.org/10.3133/ofr76343

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Pages 9415-9416]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4202]


=======================================================================
-----------------------------------------------------------------------

FEDERAL MARITIME COMMISSION


Notice of Hearing Schedule; Passenger Vessel Financial 
Responsibility

    The Commission has established the following allotment of time and 
order of presentation for the hearing concerning the Commission's 
Passenger Vessel Financial Responsibility Program. The hearing will 
convene at 10 a.m., March 3, 2010, in the Commission's Main Hearing 
Room, Room 100, 800 North Capitol Street, NW., Washington, DC 20573. In 
the event that additional time is needed to hear all participants and 
allow presenters to field questions from the Commission, an afternoon 
session will be convened.
    The due date for submitting the original and 15 copies of 
participant's prepared hearing statement is Friday, February 26, 2010. 
All written submissions, except for confidential business information, 
will be available for public inspection.

------------------------------------------------------------------------
                                                          Time allotment
            Company                   Participant(s)        (in minutes)
------------------------------------------------------------------------
American Cruise Lines Inc......  Charles A. Robertson,                15
                                  Chairman & Chief
                                  Executive Officer.
Carnival Corporation & PLC.....  David Bernstein, Senior              15
                                  Vice President & Chief
                                  Financial Officer.
Crystal Cruises, Inc...........  Ann G. Miller, Law                   15
                                  Offices of Ann G.
                                  Miller.
Cruise Lines International       Terry L. Dale,                       15
 Association.                     President and CEO, J.
                                  Michael Cavanaugh,
                                  Holland & Knight LLP.
Passenger Vessel Association...  Ed Welch, Legislative                15
                                  Director.
------------------------------------------------------------------------



[[Page 9416]]

Karen V. Gregory,
Secretary.
[FR Doc. 2010-4202 Filed 3-1-10; 8:45 am]
BILLING CODE 6730-01-P
# C_2017038EN.01002701.xml

| 6.2.2017 | EN | Official Journal of the European Union | C 38/27 |
| --- | --- | --- | --- |

6.2.2017

EN

Official Journal of the European Union

C 38/27

---

Judgment of the General Court of 15 December 2016 — Spain v Commission

(Case T-808/14) (1)

1

((State aid - Digital television - Aid for the deployment of digital terrestrial television in remote and less-urbanised areas of Castilla-La Mancha - Decision declaring the aid incompatible with the internal market - Concept of ‘undertaking’ - Economic activity - Advantage - Service of general economic interest - Distortion of competition - Article 107(3)(c) TFEU - Duty of diligence - Reasonable period - Legal certainty - Equal treatment - Proportionality - Subsidiarity - Right to information))

(2017/C 038/36)

Language of the case: Spanish

Parties

Parties

Applicant: Kingdom of Spain (represented by: A. Rubio González, and subsequently by A. Gavela Llopis, abogados del Estado)

Applicant:

Defendant: European Commission (represented by: É. Gippini Fournier, P. Němečková and B. Stromsky, acting as Agents)

Defendant:

Re:

Re:

Application based on Article 263 TFEU and seeking the annulment of Commission Decision C(2014) 6846 final of 1 October 2014 on State aid SA.27408 ((C 24/2010) (ex NN 37/2010, ex CP 19/2009)) implemented by the authorities of Castilla-La Mancha for the deployment of digital terrestrial television in remote and less urbanised areas of Castilla-La Mancha, as amended by Decision C(2015) 7193 final of 20 October 2015 correcting certain errors contained in Decision C(2014) 6846 final.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders the Kingdom of Spain to pay the costs. |
| --- | --- |

2.

Orders the Kingdom of Spain to pay the costs.

---

(1)  OJ C 34, 2.2.2015.

1

---
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATMENT OF VOLUNTEER BANCORP, INC. FOR THE YEAR ENDED
DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       2,771,810
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                             6,446,143
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                 13,518,893
<INVESTMENTS-CARRYING>                       1,603,847
<INVESTMENTS-MARKET>                         1,596,156
<LOANS>                                     35,337,260
<ALLOWANCE>                                    457,432
<TOTAL-ASSETS>                              63,393,209
<DEPOSITS>                                  55,677,131
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                            869,170
<LONG-TERM>                                  3,450,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         5,258
<OTHER-SE>                                   3,391,650
<TOTAL-LIABILITIES-AND-EQUITY>              63,393,209
<INTEREST-LOAN>                              2,859,280
<INTEREST-INVEST>                              947,065
<INTEREST-OTHER>                               227,391
<INTEREST-TOTAL>                             4,033,736
<INTEREST-DEPOSIT>                           1,950,458
<INTEREST-EXPENSE>                           2,250,607
<INTEREST-INCOME-NET>                        1,783,129
<LOAN-LOSSES>                                  100,000
<SECURITIES-GAINS>                              13,311
<EXPENSE-OTHER>                              1,723,418
<INCOME-PRETAX>                                138,843
<INCOME-PRE-EXTRAORDINARY>                      84,520
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    84,520
<EPS-PRIMARY>                                     0.17
<EPS-DILUTED>                                        0
<YIELD-ACTUAL>                                    8.43
<LOANS-NON>                                     97,919
<LOANS-PAST>                                    84,007
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               401,066
<CHARGE-OFFS>                                   79,228
<RECOVERIES>                                    35,594
<ALLOWANCE-CLOSE>                              457,432
<ALLOWANCE-DOMESTIC>                           457,432
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1085 Angiotensin I and renin test system. ( a ) *Identification.* An angiotensin I and renin test system is a device intended to measure the level of angiotensin I generated by renin in plasma. Angiotensin I measurements are used in the diagnosis and treatment of certain types of hypertension.
( b ) *Classification.* Class II.
§ 524.2099 Selamectin and sarolaner. ( a ) *Specifications.* Each milliliter (mL) of solution contains 60 milligrams (mg) selamectin and 10 mg sarolaner. The drug is provided in single dose tubes containing 0.25, 0.5, or 1 mL of solution.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Administer 2.7 mg selamectin per pound (/lb) (6 mg per kilogram (/kg)) of body weight and 0.45 mg/lb sarolaner (1 mg/kg) by emptying the contents of the tube on the back of the animal at the base of the neck in front of the shoulder blades.
( 2 ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis.* Kills adult fleas (*Ctenocephalides felis*) and is indicated for the treatment and prevention of flea infestations; the treatment and control of tick infestations with *Amblyomma americanum* (lone star tick), *Amblyomma maculatum* (Gulf Coast tick), *Dermacentor variabilis* (American dog tick), and *Ixodes scapularis* (black-legged tick), the treatment and control of ear mite (*Otodectes cynotis*) infestations; and the treatment and control of roundworm (*Toxocara cati*) and intestinal hookworm (*Ancylostoma tubaeforme*) infections in cats and kittens 8 weeks of age and older, and weighing 2.8 pounds or greater.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[84 FR 12494, Apr. 2, 2019, as amended at 89 FR 14410, Feb. 27, 2024]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7616 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7616

To prohibit the use of Federal funds to provide assistance for building 
            in, or rebuilding Gaza, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 11, 2024

   Mr. Mast introduced the following bill; which was referred to the 
                      Committee on Foreign Affairs

_______________________________________________________________________

                                 A BILL

 
To prohibit the use of Federal funds to provide assistance for building 
            in, or rebuilding Gaza, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PROHIBITION ON FUNDING.

    No Federal funds are authorized to be appropriated or otherwise 
made available to build in, or rebuild the Gaza strip on or after the 
date of the enactment of this Act.
                                 <all>
```
#### § 820.130 Device packaging.

Each manufacturer shall ensure that device packaging and shipping containers are designed and constructed to protect the device from alteration or damage during the customary conditions of processing, storage, handling, and distribution.
#### § 320.28 Correlation of bioavailability with an acute pharmacological effect or clinical evidence.

Correlation of in vivo bioavailability data with an acute pharmacological effect or clinical evidence of safety and effectiveness may be required if needed to establish the clinical significance of a special claim, e.g., in the case of an extended release preparation.

[42 FR 1648, Jan. 7, 1977, as amended at 67 FR 77674, Dec. 19, 2002]
<TABLE> <S> <C>




<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF PROSOURCE, INC. AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                                <C>                    <C>         
<PERIOD-TYPE>                      YEAR                   YEAR        
<FISCAL-YEAR-END>                  DEC-27-1997            DEC-27-1996 
<PERIOD-END>                       DEC-27-1997            DEC-27-1996 
<CASH>                              12,501,000              2,763,000      
<SECURITIES>                                 0                      0      
<RECEIVABLES>                      226,332,000            221,674,000      
<ALLOWANCES>                         4,085,000              2,334,000      
<INVENTORY>                        160,621,000            144,040,000      
<CURRENT-ASSETS>                   410,993,000            384,430,000      
<PP&E>                              89,368,000             72,181,000      
<DEPRECIATION>                      29,407,000             22,544,000      
<TOTAL-ASSETS>                     548,101,000            503,724,000      
<CURRENT-LIABILITIES>              304,965,000            298,882,000      
<BONDS>                            174,200,000            112,584,000      
<PREFERRED-MANDATORY>                        0                      0      
<PREFERRED>                                  0                      0      
<COMMON>                                93,000                 94,000      
<OTHER-SE>                          64,322,000             78,421,000      
<TOTAL-LIABILITY-AND-EQUITY>       548,101,000            503,724,000      
<SALES>                          3,901,165,000          4,125,054,000      
<TOTAL-REVENUES>                 3,901,165,000          4,125,054,000      
<CGS>                            3,591,368,000          3,806,811,000      
<TOTAL-COSTS>                    3,591,368,000          3,806,811,000      
<OTHER-EXPENSES>                   302,080,000            345,494,000      
<LOSS-PROVISION>                     2,275,000              1,682,000      
<INTEREST-EXPENSE>                  11,745,000             14,824,000      
<INCOME-PRETAX>                     (1,476,000)           (40,381,000)     
<INCOME-TAX>                           485,000             15,410,000     
<INCOME-CONTINUING>                   (991,000)           (24,971,000)     
<DISCONTINUED>                               0                      0      
<EXTRAORDINARY>                     (6,262,000)               610,000      
<CHANGES>                           (6,426,000)                     0      
<NET-INCOME>                       (13,679,000)           (24,361,000)      
<EPS-PRIMARY>                            (1.47)                 (4.20)      
<EPS-DILUTED>                            (1.47)                 (4.20)      
                                                                           

</TABLE>
#### § 822.29 May I request a waiver of a specific requirement of this part?

You may request that we waive any specific requirement of this part. You may submit your request, with supporting documentation, separately or as a part of your postmarket surveillance submission to the address in § 822.8.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1540 Osmolality test system. ( a ) *Identification.* An osmolality test system is a device intended to measure ionic and nonionic solute concentration in body fluids, such as serum and urine. Osmolality measurement is used as an adjunct to other tests in the evaluation of a variety of diseases, including kidney diseases (e.g., chronic progressive renal failure), diabetes insipidus, other endocrine and metabolic disorders, and fluid imbalances.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2307, Jan. 14, 2000]
38887.

#### JACKSON v. REDWOOD RESTAURANT & BARS, INC.

Decided June 22, 1961.

*J. Sidney Lanier,*for plaintiff in error.

*Miles B. Sams,*contra.

Townsend, Presiding Judge.

Service by mail of a bill of exceptions upon parties residing in this State being insufficient, and there being no other return, acknowledgment, or waiver of service, the motion to dismiss this bill of exceptions must be sustained. *Feldman v. Benson,*90 Ga. App. 824 (84 SE2d 710).

*Writ of error dismissed.*

*Frankum and Jordan, JJ., concur.*
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                            DEC-31-2000
<PERIOD-START>                               JAN-01-2000
<PERIOD-END>                                 Mar-31-2000
<CASH>                                             3,107
<SECURITIES>                                           0
<RECEIVABLES>                                     17,517
<ALLOWANCES>                                           0
<INVENTORY>                                        8,600
<CURRENT-ASSETS>                                  30,634
<PP&E>                                             4,668
<DEPRECIATION>                                         0
<TOTAL-ASSETS>                                    48,834
<CURRENT-LIABILITIES>                             23,402
<BONDS>                                                0
<PREFERRED-MANDATORY>                                 98
<PREFERRED>                                            0
<COMMON>                                               0
<OTHER-SE>                                        (1,023)
<TOTAL-LIABILITY-AND-EQUITY>                      48,834
<SALES>                                           15,928
<TOTAL-REVENUES>                                  15,928
<CGS>                                             10,212
<TOTAL-COSTS>                                      4,543
<OTHER-EXPENSES>                                       0
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                   934
<INCOME-PRETAX>                                      271
<INCOME-TAX>                                          30
<INCOME-CONTINUING>                                  306
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                         306
<EPS-BASIC>                                         0.03
<EPS-DILUTED>                                       0.03



</TABLE>
IN THE COURT OF CRIMINAL APPEALS

OF TEXAS

NO. WR-90,928-01

EX PARTE MEGAN MARIE ALEGRIA, Applicant

ON APPLICATION FOR A WRIT OF HABEAS CORPUS

CAUSE NO. 1327659-A IN THE 184TH DISTRICT COURT

FROM HARRIS COUNTY

Per curiam. KEASLER and YEARY, JJ., concurring.

O P I N I O N

Applicant was convicted of possession of a controlled substance and sentenced to two years’

imprisonment. Applicant filed this application for a writ of habeas corpus in the county of

conviction, and the district clerk forwarded it to this Court. SeeTEX.CODE CRIM. PROC. art. 11.07.

Applicant contends, among other things, that her due process rights were violated because

after she pleaded guilty, the evidence in her case was analyzed and found not to contain a controlled

substance or dangerous drug. The trial court made findings of fact and conclusions of law and

recommended that we set aside Applicant’s conviction.

Relief is granted. Ex parte Mable, 443 S.W.3d 129 (Tex. Crim. App. 2014). The judgment

in cause number 1327659 in the 184th District Court of Harris County is set aside, and Applicant
2

is remanded to the custody of the Sheriff of Harris County to answer the charges as set out in the

information. The trial court shall issue any necessary bench warrant within ten days from the date

of this Court’s mandate.

Copies ofthis opinion shall be sent to the Texas Department of Criminal Justice–Correctional

Institutions Division and the Board of Pardons and Paroles.

Delivered: March 11, 2020

Do not publish
§ 582.1141 Ammonium phosphate. ( a ) *Product.* Ammonium phosphate (mono- and dibasic).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.